• YOU ARE AT |
  • Home
  • News
  • Biosidus at ECTRIMS 2016

International Presence

  • With more than two decades of expertise in the manufacture and distribution of high quality biosimilar products in emerging market countries, a strong portfolio and pipeline of products, significant development and manufacturing capabilities and an established network of distribution partners, we believe we are well positioned to take advantage of opportunities for growth in the global biosimilar therapeutics market

    / More


Biosidus at ECTRIMS 2016

The European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) has been gathering the world’s most eminent global MS experts on a yearly basis. This year, London (UK) will host ECTRIMS 2016 in September 14-16.

This is the fourth ECTRIMS edition having Biosidus S.A. as outstanding exhibitor of the Argentine Biotechnology. Blastoferon® (interferon beta 1a) is Biosidus’s remarkable R&D contribution to the Multiple Sclerosis immunomodulating therapy showing its commitment to the treatment of this disabling disease which affects more than 8000 patients solely in Argentina. We will be glad to meet you in our booth #E20.